
Merck & Co., Inc. (NYSE:MRK - Free Report) - Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Merck & Co., Inc. in a research note issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will earn $8.66 per share for the year, down from their prior estimate of $8.88. Cantor Fitzgerald currently has a "Cautious" rating on the stock. The consensus estimate for Merck & Co., Inc.'s current full-year earnings is $9.01 per share. Cantor Fitzgerald also issued estimates for Merck & Co., Inc.'s FY2026 earnings at $9.55 EPS.
Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 25th. Citigroup restated a "neutral" rating and issued a $84.00 price target (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Morgan Stanley reduced their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Thursday. Finally, Guggenheim reissued a "buy" rating and set a $115.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $108.69.
Read Our Latest Stock Analysis on Merck & Co., Inc.
Merck & Co., Inc. Stock Performance
Shares of MRK stock traded up $0.35 on Thursday, hitting $84.06. The company had a trading volume of 14,718,254 shares, compared to its average volume of 13,408,952. The company has a 50-day moving average price of $79.06 and a 200-day moving average price of $86.71. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $129.93. The firm has a market cap of $211.08 billion, a P/E ratio of 10.75, a price-to-earnings-growth ratio of 0.87 and a beta of 0.39. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a return on equity of 43.23% and a net margin of 27.27%. Merck & Co., Inc.'s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.07 earnings per share.
Merck & Co., Inc. Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, July 8th. Investors of record on Monday, June 16th were paid a dividend of $0.81 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.85%. Merck & Co., Inc.'s payout ratio is currently 47.16%.
Insider Buying and Selling
In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the firm's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total value of $352,723.12. Following the sale, the senior vice president directly owned 7,778 shares in the company, valued at $643,707.28. This trade represents a 35.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Quilter Plc boosted its holdings in shares of Merck & Co., Inc. by 5.6% in the 1st quarter. Quilter Plc now owns 1,180,797 shares of the company's stock valued at $105,988,000 after buying an additional 62,933 shares in the last quarter. Simplicity Wealth LLC lifted its position in Merck & Co., Inc. by 991.7% in the first quarter. Simplicity Wealth LLC now owns 33,394 shares of the company's stock valued at $2,997,000 after acquiring an additional 30,335 shares during the last quarter. Napatree Capital LLC boosted its stake in Merck & Co., Inc. by 13.0% in the fourth quarter. Napatree Capital LLC now owns 4,220 shares of the company's stock valued at $420,000 after acquiring an additional 485 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Merck & Co., Inc. by 13.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 56,566 shares of the company's stock worth $5,118,000 after purchasing an additional 6,850 shares during the last quarter. Finally, Summit Financial LLC increased its position in shares of Merck & Co., Inc. by 34.2% during the fourth quarter. Summit Financial LLC now owns 102,099 shares of the company's stock worth $10,229,000 after purchasing an additional 25,997 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.
About Merck & Co., Inc.
(
Get Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report